机构名称：
¥ 1.0
2。GLP-1投资组合的GLP-1的兴起为整个药物开发生命周期中的肥胖和与肥胖相关的资产创造了巨大的机会。在这种现象的另一侧，GLP-1在治疗肥胖和下游疾病方面的成功和临床功效对药物和MedTech公司产生了极大的焦虑，这些公司的治疗剂可能会受到干扰，包括心血管疾病和终末期肾脏疾病。我们的客户一直在问我们：“ GLP-1的影响是什么？”不管潜在的疾病状态如何。We predict that pharma companies will seek out superior obesity drugs 3 or complementary assets 4 and flock to “GLP-1-resistant” therapeutic areas like rare diseases, neurology, and oncology, and we think MedTech companies may search for assets that are not impacted by GLP-1s or assets for which an increase in longevity could portend an increase in utilization.
生命科学并购2023趋势
主要关键词
相关文件推荐
